Eculizumab is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
It inhibits the cleavage of C5 by the C5 convertase into C5a, a potent anaphylatoxin with prothrombotic and proinflammatory properties, and C5b, which then forms the terminal complement complex C5b-9 which also has prothrombotic and proinflammatory effects. Both C5a and C5b-9 cause the complement-mediated events that are characteristic of PNH and aHUS.
It is administered through intravenous infusion every 2 weeks.
In 2016, it sold €500 million in Europe.
Labs that test for drug level: